{
    "2018-02-02": [
        [
            {
                "time": "2018-02-02",
                "original_text": "Validea Peter Lynch Strategy Daily Upgrade Report - 2/2/2018",
                "features": {
                    "keywords": [
                        "Peter Lynch",
                        "Upgrade",
                        "Strategy"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-02",
                "original_text": "Validea John Neff Strategy Daily Upgrade Report - 2/2/2018",
                "features": {
                    "keywords": [
                        "John Neff",
                        "Upgrade",
                        "Strategy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Novartis’s 4Q17 Earnings: Segment-Wise Revenues",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Earnings",
                        "Segment-Wise",
                        "Revenues"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "AstraZeneca’s 4Q17 Earnings: Analyst Estimates",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Earnings",
                        "Analyst",
                        "Estimates"
                    ],
                    "sentiment_score": 0.55,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}